Bellevue Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $304M | Buy |
681,908
+788
| +0.1% | +$367K | 7.25% | 1 |
|
|
2025
Q4 | $309M | Buy |
681,120
+175,315
| +35% | +$75.6M | 5.85% | 4 |
|
|
2025
Q3 | $198M | Buy |
505,805
+64,195
| +15% | +$26.8M | 4.12% | 6 |
|
|
2025
Q2 | $197M | Buy |
441,610
+28,539
| +7% | +$13.2M | 4.33% | 8 |
|
|
2025
Q1 | $200M | Sell |
413,071
-74,363
| -15% | -$34.7M | 4.49% | 8 |
|
|
2024
Q4 | $196M | Sell |
487,434
-83,972
| -15% | -$38.9M | 3.78% | 6 |
|
|
2024
Q3 | $266M | Sell |
571,406
-22,055
| -4% | -$10.6M | 4.31% | 3 |
|
|
2024
Q2 | $278M | Sell |
593,461
-75,289
| -11% | -$32.7M | 4.52% | 3 |
|
|
2024
Q1 | $280M | Sell |
668,750
-67,640
| -9% | -$28.6M | 4.26% | 4 |
|
|
2023
Q4 | $300M | Sell |
736,390
-266,345
| -27% | -$98.4M | 4.58% | 4 |
|
|
2023
Q3 | $349M | Sell |
1,002,735
-94,431
| -9% | -$33M | 5.62% | 3 |
|
|
2023
Q2 | $386M | Sell |
1,097,166
-48,529
| -4% | -$16.4M | 5.51% | 1 |
|
|
2023
Q1 | $361M | Buy |
1,145,695
+49,667
| +5% | +$14.9M | 5.24% | 1 |
|
|
2022
Q4 | $317M | Sell |
1,096,028
-62,098
| -5% | -$18.9M | 4.2% | 4 |
|
|
2022
Q3 | $335M | Sell |
1,158,126
-18,010
| -2% | -$5.18M | 4.81% | 2 |
|
|
2022
Q2 | $331M | Sell |
1,176,136
-304,117
| -21% | -$81.4M | 4.69% | 3 |
|
|
2022
Q1 | $386M | Sell |
1,480,253
-311,508
| -17% | -$73.9M | 4.49% | 1 |
|
|
2021
Q4 | $393M | Buy |
1,791,761
+30,145
| +2% | +$5.86M | 4.06% | 2 |
|
|
2021
Q3 | $320M | Buy |
1,761,616
+27,922
| +2% | +$5.45M | 3.24% | 2 |
|
|
2021
Q2 | $350M | Buy |
1,733,694
+356,990
| +26% | +$74.7M | 3.41% | 3 |
|
|
2021
Q1 | $296M | Buy |
1,376,704
+137,719
| +11% | +$30.2M | 3.13% | 4 |
|
|
2020
Q4 | $293M | Buy |
1,238,985
+278,385
| +29% | +$63.9M | 3.35% | 4 |
|
|
2020
Q3 | $261M | Sell |
960,600
-22,000
| -2% | -$6.07M | 3.61% | 4 |
|
|
2020
Q2 | $285M | Sell |
982,600
-290,489
| -23% | -$78.8M | 4.04% | 4 |
|
|
2020
Q1 | $303M | Sell |
1,273,089
-116,200
| -8% | -$26.7M | 5.87% | 2 |
|
|
2019
Q4 | $304M | Sell |
1,389,289
-39,850
| -3% | -$8.07M | 4.82% | 4 |
|
|
2019
Q3 | $242M | Buy |
1,429,139
+8,650
| +0.6% | +$1.53M | 4.5% | 4 |
|
|
2019
Q2 | $260M | Buy |
1,420,489
+1,303,500
| +1,114% | +$228M | 4.45% | 4 |
|
|
2019
Q1 | $21.5M | Buy |
116,989
+2,289
| +2% | +$423K | 1.18% | 24 |
|
|
2018
Q4 | $19M | Buy |
114,700
+74,206
| +183% | +$12.9M | 1.25% | 23 |
|
|
2018
Q3 | $7.8M | Sell |
40,494
-1,800
| -4% | -$321K | 0.5% | 57 |
|
|
2018
Q2 | $7.19M | Sell |
42,294
-54,516
| -56% | -$8.45M | 0.61% | 51 |
|
|
2018
Q1 | $15.8M | Buy |
96,810
+600
| +0.6% | +$98K | 1.56% | 21 |
|
|
2017
Q4 | $14.4M | Buy |
96,210
+36,410
| +61% | +$5.39M | 1.51% | 21 |
|
|
2017
Q3 | $9.09M | Sell |
59,800
-8,600
| -13% | -$1.29M | 0.95% | 36 |
|
|
2017
Q2 | $8.81M | Sell |
68,400
-7,600
| -10% | -$915K | 1.04% | 38 |
|
|
2017
Q1 | $8.31M | Sell |
76,000
-5,000
| -6% | -$440K | 1.11% | 34 |
|
|
2016
Q4 | $5.97M | Sell |
81,000
-4,000
| -5% | -$325K | 1.22% | 27 |
|
|
2016
Q3 | $7.41M | Buy |
85,000
+19,000
| +29% | +$1.8M | 1.34% | 26 |
|
|
2016
Q2 | $5.68M | Hold |
66,000
| – | – | 1.07% | 34 |
|
|
2016
Q1 | $5.25M | Buy |
+66,000
| New | +$5.97M | 0.95% | 38 |
|
Other funds holding VRTX
VCM
VPM
Bellevue Group's VRTX Position: Q1 2026 in Review
Bellevue Group increased its Vertex Pharmaceuticals (VRTX) stake by 0.12% in Q1 2026, buying an estimated $367K and bringing the position to 681,908 shares worth $304M. The position accounts for 7.25% of the portfolio, ranked #1.
Bellevue Group first reported a position in VRTX in Q1 2016 and has held it in 41 quarters since. The position peaked at $393M in Q4 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Bellevue Group held 681,908 shares of Vertex Pharmaceuticals worth $304M as of Q1 2026.
- Bellevue Group bought 788 Vertex Pharmaceuticals shares in Q1 2026, an estimated $367K.
- Vertex Pharmaceuticals made up 7.25% of Bellevue Group's portfolio in Q1 2026, its #1 holding.
- Bellevue Group first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
- Bellevue Group's Vertex Pharmaceuticals position peaked at $393M in Q4 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.